Dalrada Financial Corporation Files Form 10-Q, Announces Third Quarter Revenue of $10.3 Million
Dalrada Financial (OTCQB: DFCO) filed a Form 10-Q for Q3 2024, revealing a revenue of $10.3 million, driven primarily by its pharmaceutical subsidiary, Genefic Specialty Pharmacy. Genefic accounted for $8.6 million, an 80% increase from Q3 2023 and a 95.5% rise from the previous quarter. The company also converted $13.3 million of affiliate debt to Series I preferred shares, reducing net losses to $2.9 million, the lowest since 2021. CEO Brian Bonar emphasized ongoing efforts to clear debt and reduce expenditures, with a net equity of $8.8 million. Dalrada anticipates continued growth in Q4 and a year-over-year revenue increase by the end of fiscal 2024.
- Q3 2024 revenue reached $10.3 million.
- Genefic Specialty Pharmacy accounted for $8.6 million of the revenue, an 80% increase from Q3 2023.
- Revenue from Genefic increased 95.5% from the previous quarter.
- $13.3 million of affiliate debt was converted to Series I preferred shares.
- Net losses were reduced to $2.9 million, the lowest since 2021.
- Net equity is currently $8.8 million.
- Ongoing efforts to reduce expenditures and clear debt.
- Anticipated quarter-to-quarter growth in Q4.
- Expected year-over-year revenue increase by the end of fiscal 2024.
- Despite revenue growth, the company reported net losses of $2.9 million.
- The company's financial health is still reliant on significant debt conversion.
Company’s pharmaceutical subsidiary continues to drive impressive growth accounting for nearly
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Dalrada Financial Corporation (OTCQB: DFCO, “Dalrada,” “the Company”), announced today it had filed a Form 10-Q for the quarter ended March 31, 2024, posting
“Q3 showed us that the pharmaceutical market is thriving. Driven by our Genefic Specialty Pharmacy subsidiary, our health segment saw
Notably, Dalrada’s health segment, Genefic, posted a revenue increase of
Important highlights from Q3 2024:
- Dalrada overall revenue:
$10.3 million - Genefic revenue:
$8.6 million - Up
$4.2 million (95.5% ) from previous quarter - Up
$3.8 million (80.1% increase from Q3 2023)
- Genefic revenue:
$13.3 million of affiliate debt converted to Series I preferred shares
“The company continues to make tremendous strides in clearing debt and reducing expenditures while increasing revenue. I’m pleased to report that with this latest filing, Dalrada’s net equity is currently
The Dalrada executive team expects ongoing quarter-to-quarter growth during Q4 as well as a year-over-year revenue increase by the end of the fiscal year 2024 (June 30).
About Dalrada Corporation
Dalrada Financial Corporation (OTCQB: DFCO) is a multi-national holding company that develops, manufactures, and sells a robust suite of products and services in the Clean Energy and Health Care sectors. Dalrada’s core segments include Dalrada Climate Technology, which offers cutting-edge heat pump technology for industrial and residential applications, and Genefic Specialty Pharmacy, which provides end-to-end prescription services as well as patient advocacy and support.
Dalrada Financial Corporation consistently drives innovation that delivers maximum impact, bringing increased value to its shareholders.
For more information, please visit www.dalrada.com, and follow us on LinkedIn, Facebook, Twitter, and YouTube.
About Genefic
A wholly-owned subsidiary of Dalrada Financial Corporation, Genefic proudly delivers frontline health products and services through redesigned systems and reimagined patient care. Genefic’s unique pharmacy solution, Genefic Specialty Pharmacy, offers more than 30 years of dedicated expertise providing patient advocacy through end-to-end prescription services, medical education, and patient advocacy and support.
Forward-Looking Statements
Statements contained in this press release, other than statements of historical fact, particularly statements relating to cost reductions and the anticipated pre-tax savings from the cost reduction program, restructuring costs, footprint rationalization, simplifying and streamlining our operations, reducing complexity, enhancing the speed of decision-making, leveraging our sourcing capabilities and the timing of implementation and completion of the cost reduction program, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the beliefs and assumptions of management based on information available to us at the time such statements are made. These statements, which are generally identifiable by the use of the words “will,” “believe,” “expect,” “intend,” “anticipate,” “estimate,” “forecast,” “project,” “plan,” and similar expressions, are subject to certain risks and uncertainties, are made as of the date hereof, and we undertake no duty or obligation to update them. Forward-looking statements are subject to the occurrence of many events outside the Company’s control and actual results and the timing of events may differ materially from those suggested or implied by such forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the US Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K.
Media contact: Michael Eslinger meslinger@dalrada.com
FAQ
What was Dalrada Financial 's Q3 2024 revenue?
How much revenue did Genefic Specialty Pharmacy generate in Q3 2024?
What was the increase in Genefic Specialty Pharmacy's revenue from Q3 2023?
How did Dalrada Financial address its affiliate debt in Q3 2024?
What are Dalrada Financial 's net losses for Q3 2024?
What is Dalrada Financial 's net equity as of Q3 2024?
What growth does Dalrada Financial anticipate for Q4 2024?
What is Dalrada Financial 's revenue forecast for the fiscal year 2024?
